Li-Fraumeni syndrome

Li-Fraumeni syndrome is a rare inherited condition causing a significantly increased lifetime risk of developing several types of cancer, often at a younger age than usual, including breast cancer, sarcomas, brain tumours and adrenal cancer. It results from a mutation in the TP53 gene, which normally helps protect cells from becoming cancerous.

It's caused by an inherited mutation in the TP53 tumour suppressor gene, passed on in an autosomal dominant pattern, meaning an affected parent has a 50% chance of passing the mutation to each child. Some cases arise from a new mutation with no family history.

There are no symptoms of the syndrome itself; rather, it presents through the development of one or more cancers, often at an unusually young age, or through a strong family history of varied cancer types across generations. Genetic testing is used to confirm the diagnosis rather than relying on symptoms alone.

Yes, it carries a very high lifetime risk of multiple cancers, often starting in childhood or young adulthood, making intensive surveillance essential. Regular specialist screening significantly improves the chances of catching cancers early when they're most treatable.

Yes, it's a hereditary genetic condition, and genetic testing is recommended for affected individuals and their close relatives to guide personalised surveillance programmes. Genetic counselling is an important part of managing this diagnosis for the whole family.

There's no cure for the underlying genetic mutation, but intensive surveillance protocols, including regular whole-body MRI scans, aim to detect any cancers at the earliest, most treatable stage. Managing risk through surveillance and, where relevant, preventive measures is the mainstay of care.

Management involves a structured, lifelong surveillance programme including regular whole-body MRI, breast screening, and other targeted investigations based on individual risk, alongside genetic counselling for the whole family. This is usually coordinated through a specialist clinical genetics service.

Surveillance protocols typically involve annual whole-body MRI and other specific screening tests, tailored to age and individual risk factors, continuing throughout life given the ongoing elevated cancer risk. Your genetics team will provide a personalised screening schedule.

Both are inherited cancer predisposition syndromes, but Li-Fraumeni syndrome, caused by TP53 mutations, carries risk across a much broader range of cancer types starting at a younger age, while BRCA mutations primarily increase risk of breast and ovarian cancer. Different genes require different, tailored surveillance approaches.

A strong family history of varied cancers, particularly at young ages, should prompt referral to clinical genetics for assessment. Private genetics consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.